186 related articles for article (PubMed ID: 35173803)
1. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis.
Li M; Ge F; Guo R; Ruan Z; Gao Y; Niu C; Lin H; Zhao Z; Zhou Y; Li Z; Chang T
Ther Adv Neurol Disord; 2019; 12():1756286419876521. PubMed ID: 35173803
[TBL] [Abstract][Full Text] [Related]
2. Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China.
Ding J; Zhao S; Ren K; Dang D; Li H; Wu F; Zhang M; Li Z; Guo J
BMC Neurol; 2020 Jun; 20(1):238. PubMed ID: 32527235
[TBL] [Abstract][Full Text] [Related]
3. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: A Systematic Review and Meta-analysis.
Fang CEH; Bokre D; Wong SH
Neurology; 2023 Oct; 101(16):e1594-e1605. PubMed ID: 37643888
[TBL] [Abstract][Full Text] [Related]
5. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
[TBL] [Abstract][Full Text] [Related]
6. Thymectomy in ocular myasthenia gravis before generalization results in a higher remission rate.
Li F; Li Z; Chen Y; Bauer G; Uluk D; Elsner A; Swierzy M; Ismail M; Meisel A; Rückert JC
Eur J Cardiothorac Surg; 2020 Mar; 57(3):478-487. PubMed ID: 31628812
[TBL] [Abstract][Full Text] [Related]
7. Ocular myasthenia gravis - How effective is low dose prednisone long term?
Verma R; Wolfe GI; Kupersmith MJ
J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
[TBL] [Abstract][Full Text] [Related]
8. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for conversion to generalization in ocular myasthenia gravis.
Witthayaweerasak J; Rattanalert N; Aui-Aree N
Medicine (Baltimore); 2021 May; 100(19):e25899. PubMed ID: 34106649
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.
Guo RJ; Gao T; Ruan Z; Zhou HY; Gao F; Xu Q; Yu LP; Wu SD; Lei T; Li HH; Sun C; Zhang M; Gao YW; Lu XD; Tang YL; Tang BL; Huo FY; Zhu Y; Li ZY; Chang T
Neurol Ther; 2022 Mar; 11(1):73-86. PubMed ID: 34729706
[TBL] [Abstract][Full Text] [Related]
11. Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: A propensity score analysis.
Ruan Z; Guo R; Zhou H; Gao F; Lin Y; Xu Q; Yu L; Wu S; Lei T; Zhang M; Gao Y; Lu X; Li H; Sun C; Tang B; Li Z; Chang T
Eur J Neurol; 2022 Jun; 29(6):1805-1814. PubMed ID: 35188698
[TBL] [Abstract][Full Text] [Related]
12. Response to treatment in pediatric ocular myasthenia gravis.
Xu L; Castro D; Reisch JS; Iannaccone ST
Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
[TBL] [Abstract][Full Text] [Related]
14. Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: A 5-year analysis.
Kemchoknatee P; Arepagorn A; Srisombut T
Asian Pac J Allergy Immunol; 2021 Oct; ():. PubMed ID: 34717528
[TBL] [Abstract][Full Text] [Related]
15. Low conversion rate of ocular to generalized myasthenia gravis in Singapore.
Teo KY; Tow SL; Haaland B; Gosavi TD; Jing-Liang L; Yew Long LO; Milea D
Muscle Nerve; 2018 May; 57(5):756-760. PubMed ID: 28981152
[TBL] [Abstract][Full Text] [Related]
16. Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset.
Zhao S; Yan X; Ding J; Ren K; Sun S; Lu J; Zhang C; Zhang K; Li Z; Guo J
Front Neurol; 2022; 13():857402. PubMed ID: 35547386
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
18. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Allen JA; Scala S; Jones HR
Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Ocular Myasthenia Gravis.
Fisher K; Shah V
Curr Treat Options Neurol; 2019 Sep; 21(10):46. PubMed ID: 31559492
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
Isshiki Y; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
